Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/115127
Title: Principles in the Management of Glioblastoma
Authors: Roda, Domingos
Veiga, Pedro
Melo, Joana Barbosa 
Carreira, Isabel Marques 
Ribeiro, Ilda Patrícia 
Keywords: genetic and epigenetic biomarkers; glioblastoma; liquid biopsies; mutations; signaling pathways; target therapies
Issue Date: 17-Apr-2024
Publisher: MDPI
Serial title, monograph or event: Genes
Volume: 15
Issue: 4
Abstract: Glioblastoma, the most aggressive and common malignant primary brain tumour, is characterized by infiltrative growth, abundant vascularization, and aggressive clinical evolution. Patients with glioblastoma often face poor prognoses, with a median survival of approximately 15 months. Technological progress and the subsequent improvement in understanding the pathophysiology of these tumours have not translated into significant achievements in therapies or survival outcomes for patients. Progress in molecular profiling has yielded new omics data for a more refined classification of glioblastoma. Several typical genetic and epigenetic alterations in glioblastoma include mutations in genes regulating receptor tyrosine kinase (RTK)/rat sarcoma (RAS)/phosphoinositide 3-kinase (PI3K), p53, and retinoblastoma protein (RB) signalling, as well as mutation of isocitrate dehydrogenase (IDH), methylation of O6-methylguanine-DNA methyltransferase (MGMT), amplification of epidermal growth factor receptor vIII, and codeletion of 1p/19q. Certain microRNAs, such as miR-10b and miR-21, have also been identified as prognostic biomarkers. Effective treatment options for glioblastoma are limited. Surgery, radiotherapy, and alkylating agent chemotherapy remain the primary pillars of treatment. Only promoter methylation of the gene MGMT predicts the benefit from alkylating chemotherapy with temozolomide and it guides the choice of first-line treatment in elderly patients. Several targeted strategies based on tumour-intrinsic dominant signalling pathways and antigenic tumour profiles are under investigation in clinical trials. This review explores the potential genetic and epigenetic biomarkers that could be deployed as analytical tools in the diagnosis and prognostication of glioblastoma. Recent clinical advancements in treating glioblastoma are also discussed, along with the potential of liquid biopsies to advance personalized medicine in the field of glioblastoma, highlighting the challenges and promises for the future.
URI: https://hdl.handle.net/10316/115127
ISSN: 2073-4425
DOI: 10.3390/genes15040501
Rights: openAccess
Appears in Collections:I&D CIBB - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
genes-15-00501 (1).pdf3.46 MBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

4
checked on Sep 23, 2024

WEB OF SCIENCETM
Citations

2
checked on Sep 2, 2024

Page view(s)

140
checked on Sep 25, 2024

Download(s)

45
checked on Sep 25, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons